MediWound Schedules Release of Financial Results for 2024

Author: Addison Perry Updated: 03-03-2025 08:20 AM

MediWound's Upcoming Financial Results Announcement

MediWound Ltd. (NASDAQ: MDWD), a leader in the development of advanced enzymatic therapeutics, is prepared to announce its financial outcomes for the fourth quarter and full year concluding December 31, 2024. The financial release is scheduled for March 19, 2025, highlighting the company’s ongoing commitment to transparency and investor engagement.

Conference Call Details

Post-release, MediWound will conduct a conference call and offer a live webcast at 8:30 a.m. Eastern Time. This event is a valuable opportunity for management to discuss the financial results in detail and to share important updates regarding the company's progress and initiatives.

How to Join the Conference Call

Participants can join the conference call by dialing the appropriate numbers shared by MediWound. To ensure efficient access, attendees are encouraged to call in at least 5 minutes before the start of the call. An archived version of the webcast will also be available for those who wish to catch up later on the Investors section of the MediWound website.

About MediWound

Headquartered in Yavne, Israel, MediWound Ltd. stands at the forefront of innovation in non-surgical tissue repair. Specializing in enzymatic therapeutics, the company offers a range of solutions designed to improve patient experiences while minimizing healthcare costs. Innovative products such as NexoBrid®, an FDA and EMA-approved orphan drug, exemplify the company's commitment to enhancing existing treatment protocols.

Innovations in Wound Care

MediWound's flagship product, NexoBrid®, addresses the crucial need for effective eschar removal in thermal burns, significantly cutting down the necessity for surgical procedures. The company's pipeline includes EscharEx®, a candidate currently in Phase III development aimed at treating chronic wounds. Early Phase II trial results suggest that EscharEx offers unique advantages over existing wound debridement treatments in terms of efficacy and market potential.

Corporate Strategy and Market Position

As MediWound continues to develop its portfolio of enzymatic therapeutics, the emphasis remains on providing innovative solutions that support both patients and healthcare providers. The management team is dedicated to enhancing MediWound’s position in the market, creating opportunities for expansion, and fostering partnerships that align with the company's vision.

Frequently Asked Questions

What date will MediWound announce its financial results?

MediWound is set to release its financial results on March 19, 2025.

How can investors participate in the financial results call?

Investors can join the conference call by dialing the provided phone numbers, ideally at least 5 minutes before the call begins.

What is NexoBrid®?

NexoBrid® is MediWound's FDA- and EMA-approved biologic used for the removal of eschar in burns, which helps reduce the need for surgery.

What is EscharEx®?

EscharEx® is a promising therapeutic candidate currently in Phase III development aimed at treating chronic wounds.

Where can I find more information about MediWound?

More information is available on MediWound's official website at www.mediwound.com.

About The Author

Hello, I'm 30-year-old financial writer and expert Addison Perry, and I love to simplify the intricacies of the financial industry. I've committed myself over the years to deciphering the subtleties of investing techniques and economic trends and converting them into doable guidance that anybody can use. My goal with writings and books is to make money interesting and approachable so that readers may take charge of their financial futures.

My enthusiasm to empowerment and education has propelled me through my career in finance. I write because I think that everyone should be able to make educated financial decisions, and I try to provide that. Regardless of experience level with investing, my work is intended to provide insightful analysis and practical advice to enable you to thrive in the always changing financial environment. I appreciate you traveling with me toward success and financial literacy.

Contact Addison Perry privately here. Or send an email with ATTN: Addison Perry as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.